Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial
Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of...
Saved in:
| Published in: | The Lancet. Haematology Vol. 12; no. 1; p. e23 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
01.01.2025
|
| Subjects: | |
| ISSN: | 2352-3026, 2352-3026 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of follicular lymphoma.
We did a single-arm, investigator-initiated, phase 2 trial at Sylvester Comprehensive Cancer Center in Miami, FL, USA. We recruited patients aged 18 years or older with histologically confirmed relapsed or refractory follicular lymphoma (grade 1-3A) treated with one or more lines of therapy and presenting with progression or relapse of disease within 24 months (POD24) after the first line of treatment, one or more Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, or second relapse, and with an Eastern Cooperative Oncology Group performance status of 0-2. Intravenous loncastuximab tesirine was administered on day 1 of a 21-day cycle, at 0·15 mg/kg for two cycles, then 0·075 mg/kg thereafter. Intravenous rituximab was administered on day 1 of cycle 1, at 375 mg/m
for four once-weekly doses, followed by one dose every 8 weeks on cycles 5, 6, and 7. At week 21, patients with a complete response discontinued loncastuximab tesirine and received two more doses of rituximab once every 8 weeks. Patients with a partial response at week 21 continued both agents for 18 more weeks. The primary endpoint was complete response rate at week 12 assessed by the Lugano 2014 classification in patients who had received at least three doses of loncastuximab tesirine. The safety analysis included all patients who received one or more doses of loncastuximab tesirine. The trial is registered with ClinicalTrials.gov, NCT04998669, and is ongoing (open to recruitment); the data cutoff for this analysis was Sept 13, 2024.
Between Jan 28, 2022, and June 3, 2024, we enrolled 39 patients (median age 68 years [IQR 58-77]; 21 [54%] male patients and 18 [46%] female patients). All patients presented with one or more GELF criteria (n=36 [92%]) or POD24 after the first line of treatment (n=20 [51%]) at baseline. As of Sept 13, 2024, the median follow-up was 18·2 months (95% CI 12·0-19·3). Week 12 complete response rate was 67% (n=26 of 39). The most common grade 3 or worse treatment-emergent adverse events (TEAEs) were lymphopenia (eight [21%] of 39 patients) and neutropenia (five [13%] patients; one of whom had a serious grade 3 TEAE of febrile neutropenia that was considered to be related to study treatment). Generalised and peripheral oedema was predominantly grade 1-2 and all cases of oedema were treatable with diuretics. Serious TEAEs that were considered to be related to study drugs occurred in four (10%) of 39 patients. No fatal TEAEs occurred.
Loncastuximab tesirine with rituximab showed clinically meaningful activity in relapsed or refractory follicular lymphoma, and had a manageable safety profile.
ADC Therapeutics and Sylvester Comprehensive Cancer Center. |
|---|---|
| AbstractList | Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of follicular lymphoma.BACKGROUNDPreliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of follicular lymphoma.We did a single-arm, investigator-initiated, phase 2 trial at Sylvester Comprehensive Cancer Center in Miami, FL, USA. We recruited patients aged 18 years or older with histologically confirmed relapsed or refractory follicular lymphoma (grade 1-3A) treated with one or more lines of therapy and presenting with progression or relapse of disease within 24 months (POD24) after the first line of treatment, one or more Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, or second relapse, and with an Eastern Cooperative Oncology Group performance status of 0-2. Intravenous loncastuximab tesirine was administered on day 1 of a 21-day cycle, at 0·15 mg/kg for two cycles, then 0·075 mg/kg thereafter. Intravenous rituximab was administered on day 1 of cycle 1, at 375 mg/m2 for four once-weekly doses, followed by one dose every 8 weeks on cycles 5, 6, and 7. At week 21, patients with a complete response discontinued loncastuximab tesirine and received two more doses of rituximab once every 8 weeks. Patients with a partial response at week 21 continued both agents for 18 more weeks. The primary endpoint was complete response rate at week 12 assessed by the Lugano 2014 classification in patients who had received at least three doses of loncastuximab tesirine. The safety analysis included all patients who received one or more doses of loncastuximab tesirine. The trial is registered with ClinicalTrials.gov, NCT04998669, and is ongoing (open to recruitment); the data cutoff for this analysis was Sept 13, 2024.METHODSWe did a single-arm, investigator-initiated, phase 2 trial at Sylvester Comprehensive Cancer Center in Miami, FL, USA. We recruited patients aged 18 years or older with histologically confirmed relapsed or refractory follicular lymphoma (grade 1-3A) treated with one or more lines of therapy and presenting with progression or relapse of disease within 24 months (POD24) after the first line of treatment, one or more Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, or second relapse, and with an Eastern Cooperative Oncology Group performance status of 0-2. Intravenous loncastuximab tesirine was administered on day 1 of a 21-day cycle, at 0·15 mg/kg for two cycles, then 0·075 mg/kg thereafter. Intravenous rituximab was administered on day 1 of cycle 1, at 375 mg/m2 for four once-weekly doses, followed by one dose every 8 weeks on cycles 5, 6, and 7. At week 21, patients with a complete response discontinued loncastuximab tesirine and received two more doses of rituximab once every 8 weeks. Patients with a partial response at week 21 continued both agents for 18 more weeks. The primary endpoint was complete response rate at week 12 assessed by the Lugano 2014 classification in patients who had received at least three doses of loncastuximab tesirine. The safety analysis included all patients who received one or more doses of loncastuximab tesirine. The trial is registered with ClinicalTrials.gov, NCT04998669, and is ongoing (open to recruitment); the data cutoff for this analysis was Sept 13, 2024.Between Jan 28, 2022, and June 3, 2024, we enrolled 39 patients (median age 68 years [IQR 58-77]; 21 [54%] male patients and 18 [46%] female patients). All patients presented with one or more GELF criteria (n=36 [92%]) or POD24 after the first line of treatment (n=20 [51%]) at baseline. As of Sept 13, 2024, the median follow-up was 18·2 months (95% CI 12·0-19·3). Week 12 complete response rate was 67% (n=26 of 39). The most common grade 3 or worse treatment-emergent adverse events (TEAEs) were lymphopenia (eight [21%] of 39 patients) and neutropenia (five [13%] patients; one of whom had a serious grade 3 TEAE of febrile neutropenia that was considered to be related to study treatment). Generalised and peripheral oedema was predominantly grade 1-2 and all cases of oedema were treatable with diuretics. Serious TEAEs that were considered to be related to study drugs occurred in four (10%) of 39 patients. No fatal TEAEs occurred.FINDINGSBetween Jan 28, 2022, and June 3, 2024, we enrolled 39 patients (median age 68 years [IQR 58-77]; 21 [54%] male patients and 18 [46%] female patients). All patients presented with one or more GELF criteria (n=36 [92%]) or POD24 after the first line of treatment (n=20 [51%]) at baseline. As of Sept 13, 2024, the median follow-up was 18·2 months (95% CI 12·0-19·3). Week 12 complete response rate was 67% (n=26 of 39). The most common grade 3 or worse treatment-emergent adverse events (TEAEs) were lymphopenia (eight [21%] of 39 patients) and neutropenia (five [13%] patients; one of whom had a serious grade 3 TEAE of febrile neutropenia that was considered to be related to study treatment). Generalised and peripheral oedema was predominantly grade 1-2 and all cases of oedema were treatable with diuretics. Serious TEAEs that were considered to be related to study drugs occurred in four (10%) of 39 patients. No fatal TEAEs occurred.Loncastuximab tesirine with rituximab showed clinically meaningful activity in relapsed or refractory follicular lymphoma, and had a manageable safety profile.INTERPRETATIONLoncastuximab tesirine with rituximab showed clinically meaningful activity in relapsed or refractory follicular lymphoma, and had a manageable safety profile.ADC Therapeutics and Sylvester Comprehensive Cancer Center.FUNDINGADC Therapeutics and Sylvester Comprehensive Cancer Center. Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity and loncastuximab tesirine. In this study, we evaluated loncastuximab tesirine combined with rituximab for second-line and later treatment of follicular lymphoma. We did a single-arm, investigator-initiated, phase 2 trial at Sylvester Comprehensive Cancer Center in Miami, FL, USA. We recruited patients aged 18 years or older with histologically confirmed relapsed or refractory follicular lymphoma (grade 1-3A) treated with one or more lines of therapy and presenting with progression or relapse of disease within 24 months (POD24) after the first line of treatment, one or more Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, or second relapse, and with an Eastern Cooperative Oncology Group performance status of 0-2. Intravenous loncastuximab tesirine was administered on day 1 of a 21-day cycle, at 0·15 mg/kg for two cycles, then 0·075 mg/kg thereafter. Intravenous rituximab was administered on day 1 of cycle 1, at 375 mg/m for four once-weekly doses, followed by one dose every 8 weeks on cycles 5, 6, and 7. At week 21, patients with a complete response discontinued loncastuximab tesirine and received two more doses of rituximab once every 8 weeks. Patients with a partial response at week 21 continued both agents for 18 more weeks. The primary endpoint was complete response rate at week 12 assessed by the Lugano 2014 classification in patients who had received at least three doses of loncastuximab tesirine. The safety analysis included all patients who received one or more doses of loncastuximab tesirine. The trial is registered with ClinicalTrials.gov, NCT04998669, and is ongoing (open to recruitment); the data cutoff for this analysis was Sept 13, 2024. Between Jan 28, 2022, and June 3, 2024, we enrolled 39 patients (median age 68 years [IQR 58-77]; 21 [54%] male patients and 18 [46%] female patients). All patients presented with one or more GELF criteria (n=36 [92%]) or POD24 after the first line of treatment (n=20 [51%]) at baseline. As of Sept 13, 2024, the median follow-up was 18·2 months (95% CI 12·0-19·3). Week 12 complete response rate was 67% (n=26 of 39). The most common grade 3 or worse treatment-emergent adverse events (TEAEs) were lymphopenia (eight [21%] of 39 patients) and neutropenia (five [13%] patients; one of whom had a serious grade 3 TEAE of febrile neutropenia that was considered to be related to study treatment). Generalised and peripheral oedema was predominantly grade 1-2 and all cases of oedema were treatable with diuretics. Serious TEAEs that were considered to be related to study drugs occurred in four (10%) of 39 patients. No fatal TEAEs occurred. Loncastuximab tesirine with rituximab showed clinically meaningful activity in relapsed or refractory follicular lymphoma, and had a manageable safety profile. ADC Therapeutics and Sylvester Comprehensive Cancer Center. |
| Author | Rosenblatt, Joseph D Stanchina, Michele D Alderuccio, Juan Pablo Kuker, Russ A Schatz, Jonathan H Lessen, David S Alencar, Alvaro J Lekakis, Lazaros J Trabolsi, Asaad Sandoval-Sus, Jose Beitinjaneh, Amer Moskowitz, Craig H Spiegel, Jay Y Pongas, Georgios Reis, Isildinha M Lossos, Izidore S |
| Author_xml | – sequence: 1 givenname: Juan Pablo surname: Alderuccio fullname: Alderuccio, Juan Pablo email: jalderuccio@med.miami.edu organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA. Electronic address: jalderuccio@med.miami.edu – sequence: 2 givenname: Alvaro J surname: Alencar fullname: Alencar, Alvaro J organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 3 givenname: Jonathan H surname: Schatz fullname: Schatz, Jonathan H organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 4 givenname: Russ A surname: Kuker fullname: Kuker, Russ A organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 5 givenname: Georgios surname: Pongas fullname: Pongas, Georgios organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 6 givenname: Isildinha M surname: Reis fullname: Reis, Isildinha M organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 7 givenname: Lazaros J surname: Lekakis fullname: Lekakis, Lazaros J organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 8 givenname: Jay Y surname: Spiegel fullname: Spiegel, Jay Y organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 9 givenname: Jose surname: Sandoval-Sus fullname: Sandoval-Sus, Jose organization: Moffitt Malignant Hematology & Cellular Therapy at Memorial Healthcare System, Pembroke Pines, FL, USA – sequence: 10 givenname: Amer surname: Beitinjaneh fullname: Beitinjaneh, Amer organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 11 givenname: Michele D surname: Stanchina fullname: Stanchina, Michele D organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 12 givenname: Asaad surname: Trabolsi fullname: Trabolsi, Asaad organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 13 givenname: Izidore S surname: Lossos fullname: Lossos, Izidore S organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 14 givenname: Joseph D surname: Rosenblatt fullname: Rosenblatt, Joseph D organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 15 givenname: David S surname: Lessen fullname: Lessen, David S organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA – sequence: 16 givenname: Craig H surname: Moskowitz fullname: Moskowitz, Craig H organization: Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/39662486$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUElOwzAUtRCIltIjgLwsUgOe4jjsUMUkVWIBrKMfx6FGzoDtCHoI7kwkWsTqv_-mxTtBh23XGoTOKLmkhMqrZ8ZTlnDC5IKJC0K4SBNxgKZ_9OE_PEHzEN4JIZRnMpX5MZrwXEomlJyi73XXaghx-LINlDiaYL1tDf60cYO93fO2xT1Ea9oYdpJx0AdT4c6PuPagY-e3uO6cs3pw4LHbNv2ma-AaAw62fXMm0WPem-X-Bd8scb-BYDDD0Vtwp-ioBhfMfHdn6PXu9mX1kKyf7h9XN-tEi0zEBFJINZMlqanKUwIsK2vCjcqgUiJTlay1SokoqZY1V4JSWZWSVZIbqSAvgc3Q4re3993HYEIsGhu0cQ5a0w2h4FRImZKcitF6vrMOZWOqovfjIH5b7CdkP-m-eRE |
| CitedBy_id | crossref_primary_10_1016_j_ejmech_2025_118114 crossref_primary_10_1016_S2352_3026_24_00375_2 crossref_primary_10_1093_oncolo_oyaf166 crossref_primary_10_3390_ijms26178662 crossref_primary_10_1007_s40259_025_00735_z crossref_primary_10_1111_imcb_70017 crossref_primary_10_3390_cancers17101602 crossref_primary_10_1016_S2152_2650_25_00357_X |
| ContentType | Journal Article |
| Copyright | Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. |
| Copyright_xml | – notice: Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1016/S2352-3026(24)00345-4 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2352-3026 |
| ExternalDocumentID | 39662486 |
| Genre | Clinical Trial, Phase II Journal Article |
| GrantInformation | ADC Therapeutics and Sylvester Comprehensive Cancer Center. |
| GroupedDBID | -RU .1- .FO 0R~ 1P~ 4.4 457 53G AAEDT AAEDW AALRI AAMRU AAQFI AAQQT AAXUO ABJNI ACGFS ADBBV AENEX AFRHN AFTJW AGCQF AITUG AJUYK ALMA_UNASSIGNED_HOLDINGS AMRAJ APXCP CGR CUY CVF EBS ECM EFKBS EIF EJD FDB HZ~ M41 NPM O9- OC~ OO- Z5R 7X8 |
| ID | FETCH-LOGICAL-c474t-a5a5c26b0f18950a27bf03e87ad8478d6fc8504b1c6f384116db62d63e68a9ba2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 13 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001401667600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2352-3026 |
| IngestDate | Sun Sep 28 11:05:39 EDT 2025 Wed Jul 23 01:47:07 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | English |
| License | Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c474t-a5a5c26b0f18950a27bf03e87ad8478d6fc8504b1c6f384116db62d63e68a9ba2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 39662486 |
| PQID | 3146650914 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_3146650914 pubmed_primary_39662486 |
| PublicationCentury | 2000 |
| PublicationDate | 2025-Jan 20250101 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – month: 01 year: 2025 text: 2025-Jan |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | The Lancet. Haematology |
| PublicationTitleAlternate | Lancet Haematol |
| PublicationYear | 2025 |
| References | 39756843 - Lancet Haematol. 2025 Jan;12(1):e3-e5. doi: 10.1016/S2352-3026(24)00375-2. |
| References_xml | – reference: 39756843 - Lancet Haematol. 2025 Jan;12(1):e3-e5. doi: 10.1016/S2352-3026(24)00375-2. |
| SSID | ssj0001376569 |
| Score | 2.3872268 |
| Snippet | Preliminary data suggest promising activity of loncastuximab tesirine in follicular lymphoma, and synergistic activity between rituximab-induced cytotoxicity... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | e23 |
| SubjectTerms | Adult Aged Antibodies, Monoclonal, Humanized Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzodiazepines Female Humans Immunoconjugates - adverse effects Immunoconjugates - therapeutic use Lymphoma, Follicular - drug therapy Male Middle Aged Neoplasm Recurrence, Local - drug therapy Rituximab - administration & dosage Rituximab - adverse effects Rituximab - therapeutic use |
| Title | Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: a single-centre, single-arm, phase 2 trial |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/39662486 https://www.proquest.com/docview/3146650914 |
| Volume | 12 |
| WOSCitedRecordID | wos001401667600001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEBZNE0IvSR9pmyYtKvTQQkRsvSz3EkJo6KFZAm1gb8tIlohh197am5L8iP7njrTe7ikQyMXYEgIjzWhG32jmI-QTt7jIaEkZoPFhUtiSgY0JPjl4q7h0Wi3JJorRyIzH5eUAuPXDtcrVnpg26qp1ESM_FqjSsdpbLk_mv1lkjYrR1YFCY4NsCnRlolQXY7PGWFB7VGK14-hnMIHnjXUSz_HP_42fufwSC7UoJu93NJPBOd997K8-JzuDq0lPl7LxgjzxzUuyfTEE01-Rvz_axkG_uLmtZ2Ap-px1TAWkEZqlXb1qrxs6FF_thy4_hXnvK9p2-B66xNhzR0Ms751utdLpHcpIO4OvFGjEIqaepUug_mj1Cd3siM6v0YRSThNzyB65Ov_26-w7G9gZmJOFXDBQoBzXNgu5KVUGvLAhE94UUKHFM5UOzqhM2tzpIIzMc11ZzSstvDZQWuCvydOmbfxbQq0B4UErkA6kVWBwBC8DL0FyGXS2Tz6uJnqC0h9DGtD49qafrKd6n7xZrtZkvizTMRF4kuPS6HcPGH1AnvFI7JuwlUOyGVD3_Xuy5f4s6r77kMQKn6PLi3-0e9eu |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Loncastuximab+tesirine+with+rituximab+in+patients+with+relapsed+or+refractory+follicular+lymphoma%3A+a+single-centre%2C+single-arm%2C+phase+2+trial&rft.jtitle=The+Lancet.+Haematology&rft.au=Alderuccio%2C+Juan+Pablo&rft.au=Alencar%2C+Alvaro+J&rft.au=Schatz%2C+Jonathan+H&rft.au=Kuker%2C+Russ+A&rft.date=2025-01-01&rft.eissn=2352-3026&rft.volume=12&rft.issue=1&rft.spage=e23&rft_id=info:doi/10.1016%2FS2352-3026%2824%2900345-4&rft_id=info%3Apmid%2F39662486&rft_id=info%3Apmid%2F39662486&rft.externalDocID=39662486 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2352-3026&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2352-3026&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2352-3026&client=summon |